

## CLAIMS

1. Orally administrable film-shaped medicament containing the active substance deoxypeganine or/and a deoxypeganine derivative.
2. Medicament according to claim 1, characterized in that it contains a pharmaceutically acceptable salt of deoxypeganine or/and a pharmaceutically acceptable salt of a derivative of deoxypeganine, with deoxypeganine hydrochloride and deoxypeganine hydrobromide being preferred as salts.
3. Medicament according to claims 1 or 2, characterized in that it is suitable for transmucosal, especially buccal, administration of the active substance(s) contained therein.
4. Medicament according to any one of the preceding claims, characterized in that it has at least one polymer-containing layer which serves as active substance reservoir and contains the active substance(s), with the polymer portion amounting to 10 to 90%, preferably 20 to 70%-wt, particularly preferably 20 to 60%-wt.
5. Medicament according to any one of the preceding claims, characterized in that it has a two-, three- or multilayer structure, with at least one layer containing an active substance selected from the group comprising deoxypeganine, deoxypeganine derivatives and salts of the said substances.
6. Medicament according to any one of the preceding claims, characterized in that the active substance content is 0.5 to 40%-wt, preferably 5 to 30%-wt.

7. Medicament according to any one of the preceding claims, characterized in that its overall thickness is 0.05 to 3 mm, preferably 0.1 to 1 mm, especially preferably 0.1 to 0.5 mm.
8. Medicament according to any one of the preceding claims, characterized in that it is mucoadhesive or has at least one mucoadhesive outer surface.
9. Medicament according to any one of the preceding claims, characterized in that it is soluble in aqueous media, especially in saliva, it being preferred that the dissolution takes place within 1 s up to 5 min, especially preferably within 3 to 30 s.
10. Medicament according to any one of the preceding claims, characterized in that it quickly disintegrates in aqueous media, especially in saliva, preferably within 1 s to 5 min, especially preferably within 3 to 30 s.
11. Medicament according to any one of the preceding claims, characterized in that it is capable of gelatinizing or swelling in aqueous media, especially in saliva.
12. Medicament according to any one of the preceding claims, characterized in that it has a depot effect or releases the active substance(s) with a delay in time, preferably over a period of time of up to 8 h, especially up to 24 h.
13. Medicament according to any one of the preceding claims, characterized in that it has at least one rapidly releasing active substance-containing layer and at least one layer with retarded active substance release.

14. Medicament according to any one of the preceding claims, characterized in that it additionally contains at least one further pharmaceutically active substance which is not selected from the group including deoxypeganine, deoxypeganine derivatives and salts of the said substances.

15. Film-shaped medicament according to any one of the preceding claims, characterized in that it contains one or more auxiliary substances.

16. Use of at least one cholinergic active substance acting on the central nervous system selected from the active substances mentioned in claims 1 and 2 for the production of an oral, film-shaped medicament for administering the said active substance(s) for the treatment of diseases or symptoms caused by acetylcholine deficiency or where such a deficiency occurs, as well as for the treatment of diseases where a deficiency of endogenous amine occurs and/or which can be favourably influenced by inhibition of monoaminoxidase.

17. Use according to claim 16, characterized in that the said film-shaped medicament is a medicament according to one of the claims 1 to 15.

18. Use according to claim 16 or 17, characterized in that the medicament is used for the treatment of Alzheimer's disease or of symptoms caused by Alzheimer's disease.

19. Use according to claim 16 or 17, characterized in that the medicament is used for the treatment of depressions, schizophrenia or manic disorders.

20. Use according to claim 16 or 17, characterized in that the medicament is used for treating chronic fatigue syndrome or disturbed sleep.

21. Use according to claim 16 or 17, characterized in that the medicament is used for treating abuse of alcohol or for treating abuse of nicotine.

22. Use according to claim 16 or 17, characterized in that the medicament is used for the therapy of abuse of chemical substances, especially psychotropic substances, or the dependence on such substances.

23. Use according to claim 16 or 17, characterized in that the medicament is used for the prophylactic treatment of poisonings caused by organophosphorous cholinesterase inhibitors.

24. Use according to claim 16 or 17, characterized in that the medicament is used for the treatment of disorders of the central nervous system, particularly impaired memory, which have been caused by the action of psychotropic substances.